Premium
Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis
Author(s) -
Basken Robyn,
Bazzell Charles M.,
Smith Richard,
Janardhanan Rajesh,
Khalpey Zain
Publication year - 2017
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.13165
Subject(s) - medicine , ventricular assist device , thrombus , thrombosis , complication , cardiology , plasminogen activator , fibrinolytic agent , surgery , tissue plasminogen activator , intensive care medicine , heart failure
Abstract Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long‐term survival without further intervention.